"Evidently, it is a case of oversight and deviation from set processes at an operative and supervisory level at the facility in question," Wockhardt Ltd Founder Chairman and Group CEO Habil Khorakiwala told shareholders at the company's 14th Annual General Meeting earlier this month.
Admittedly, it is an inexcusable lapse but the company has taken swift and definitive action, both corrective and pre-emptive, he added.
More From This Section
"These measures will ensure that the operative people in the organisation do not deviate from following the systems and processes laid down," Khorakiwala said.
In July, the Mumbai-based firm had received a warning letter from US Food and Drug Administration (USFDA) over its facility at Waluj in Maharashtra for not meeting manufacturing norms.
The company had earlier in May announced that the USFDA had issued an import alert on its Waluj facility, which makes injectables and solid dosages. According to the company's estimates, the import alert issued by the USFDA could impact the company's business by $100 million.
UK drug regulator, Medicines and Healthcare products Regulatory Agency (MHRA) had also pulled up the firm for manufacturing shortcomings.
Outlining the initiatives being taken up by the company to firm up the manufacturing process, Khorakiwala said Wockhardt has appointed a new Head of Quality reporting directly to the Managing Director.
"Secondly, we are working with several international consultants and advisors to establish processes enabling a robust system of compliance that will meet all regulatory norms and requirements," he added.
The company is leveraging technology to lay down a system of checks and balances to ensure that operative personnel strictly follow and maintain established processes and protocols mandated, he said.
"We are deploying enterprise-wide software that will streamline the entire quality and compliance system across all our manufacturing facilities," Khorakiwala said.